Form S-8 CRISPR Therapeutics AG
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
CRISPR Therapeutics (CRSP) PT Lowered to $60 at RBC Capital
August 6, 2024 6:43 AM EDTRBC Capital analyst Luca Issi lowered the price target on CRISPR Therapeutics (NASDAQ: CRSP) to $60.00 (from $66.00) while maintaining a Sector Perform rating.
The analyst comments "Casgevys launch is under way with >35 ATCs activated (vs >25 last Q) and cells collected from 20... More
